An experimental two-in-one vaccine triggered strong immune responses against both the flu and SARS-CoV-2, the virus behind COVID-19, in an advanced clinical trial that included adults ages 50 and older.
Moderna representatives told news outlets that the company aspires to have the new shot approved by fall 2025 — so it won't be available by this flu season, but it might be by the next. Pfizer-BioNTech and Novavax are also working on their own COVID-flu vaccines, but Moderna is the first to release late-stage clinical trial data. People currently have to get their annual flu shots and updated COVID-19 vaccines separately.
By submitting your information you agree to the Terms & Conditions and Privacy Policy and are aged 16 or over."When we think about the combination vaccine, we often only think about the element of convenience, one shot instead of two," Ceddia told CNN."But what is really, really breakthrough is the fact that you not only offer that advantage, you also offer the proof of clinical benefit.